// App-Quantinova.ai

OP0249 : LONG-TERM EXTENSION RESULTS OF RISE-SSC, A RANDOMIZED TRIAL OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)

Researchers

Presenter

  • D. Khanna

Principal Investigators

  • M. Matucci-Cerinic

  • M. Kuwana

  • C. Denton

  • Y. Allanore

  • M. Wosnitza

  • M. E. Truchetet

  • G. Szcs

  • W. Stevens

  • V. Steen

  • C. Stagnaro

  • V. Smith

  • R. Silver

  • E. Schiopu

  • V. Riccieri

  • F. Kramer

  • S. Johnson

  • O. Ishikawa

  • T. Ishii

  • E. Hachlla

  • E. De Langhe

  • L. Czirjk

  • R. Becvr

  • T. Atsumi

  • O. Distler

Medical Centers

  • U. Michigan, Ann Arbor, United States of America

  • Univ Western Ontario, Ontario, Canada

  • University of Florence, Florence, Italy

  • Nippon Medical School, Tokyo, Japan

  • NCRI, London, United Kingdom

  • Paris Descartes University, Paris, France

  • Bayer Pharma AG, Berlin, Germany

  • Bordeaux University, Bordeaux, France

  • University of Debrecen, Debrecen, Hungary

  • St Vincent's Hospital, Melbourne, Australia

  • Georgetown Univ, Washington, United States of America

  • Univ. of Pisa, Pisa, Italy

  • Ghent University Hospital, Ghent, Belgium

  • Medical University of South Carolina, Charleston, United States of America

  • Michigan Medicine Univ Hosp, Ann Arbor, Michigan, United States of America

  • Sapienza-Univ of Rome, Rome, Italy

  • UHN, Toronto, Ontario, Canada.

  • Gunma University Hospital, Maebashi, Japan

  • Tohoku Univ Hosp, Sendai, Japan

  • Univ Hosps Leuven, Leuven, Belgium

  • Univ Pécs Medical School, Pécs, Hungary

  • Charles Univ and VFN, Prague, Czech Republic

  • Hokkaido Univ., Sapporo, Japan.

  • Univ Hosp, Zurich, Switzerland

Locations

  • United States

  • Canada

  • Italy

  • Japan

  • United Kingdom

  • France

  • Germany

  • Hungary

  • Australia

  • Belgium

  • Czech Republic

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • N/A

Drug/Treatment

  • Riociguat

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • NCT02283762

Sponsors

  • Bayer AG and Merck Sharp & Dohme Corp(MSD)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved